Eledon Pharmaceuticals, Inc. announced the enrollment of the 12th participant on March 23, 2024, in the Company?s ongoing Phase 2 BESTOW trial assessing tegoprubart head-to-head with tacrolimus for the prevention of rejection in kidney transplantation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 USD | +7.86% | +30.74% | +67.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.78% | 74.94M | |
+9.42% | 115B | |
+11.84% | 106B | |
-2.56% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- ELDN Stock
- News Eledon Pharmaceuticals, Inc.
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection